In cell models with AIM2 inflammasome activation, including HH and NAFLD, the inhibitory effect of M2exo@HMPBs on AIM2 inflammasomes was confirmed using agonists and gene knockouts. Here, AIM2 is linked to metabolic dysfunction-associated steatotic liver disease.